Ning-Yu Wang

List of Publications by Year
in descending order

51	1,127	393982	414034
papers	citations	19 h-index	32 g-index

56	56	56	1836
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor. European Journal of Medicinal Chemistry, 2022, 227, 113922.	2.6	24
2	Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer. European Journal of Medicinal Chemistry, 2022, 228, 113978.	2.6	9
3	Covalent inhibitors of EZH2: Design, synthesis and evaluation. Biomedicine and Pharmacotherapy, 2022, 147, 112617.	2.5	7
4	Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2. Journal of Medicinal Chemistry, 2021, 64, 2829-2848.	2.9	72
5	9-Sulfonyl-9(H)-Purine Derivatives Inhibit HCV Replication Via their Degradation Species. Pharmaceutical Chemistry Journal, 2021, 55, 36-45.	0.3	0
6	Design, synthesis and biological evaluations of a series of Pyrido[1,2-a]pyrimidinone derivatives as novel selective FGFR inhibitors. European Journal of Medicinal Chemistry, 2021, 220, 113499.	2.6	12
7	BRD4 inhibition sensitizes aggressive non-Hodgkin lymphomas to PI3KÎ´ inhibitors by suppressing PI3K reactivation and c-MYC expression. American Journal of Cancer Research, 2021, 11, 215-235.	1.4	0
8	A novel fixed-dose combination treatment for chronic hepatitis C, based on NS5A inhibitor fopitasvir and NS5B inhibitor sofosbuvir. Die Pharmazie, 2021, 76, 372-378.	0.3	0
9	Identification of a potent and selective phosphatidylinositol 3-kinase Î´ inhibitor for the treatment of non-Hodgkin's lymphoma. Bioorganic Chemistry, 2020, 105, 104344.	2.0	6
10	Design, synthesis and structure-activity relationship study of piperazinone-containing thieno[3,2-d]pyrimidine derivatives as new PI3KÎ´ inhibitors. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127479.	1.0	3
11	Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors. European Journal of Medicinal Chemistry, 2020, 191, 112152.	2.6	31
12	Novel Dual BET and PLK1 Inhibitor WNY0824 Exerts Potent Antitumor Effects in CRPC by Inhibiting Transcription Factor Function and Inducing Mitotic Abnormality. Molecular Cancer Therapeutics, 2020, 19, 1221-1231.	1.9	15
13	Structural characterization of a Î”3, Î”2-enoyl-CoA isomerase from Pseudomonas aeruginosa: implications for its involvement in unsaturated fatty acid metabolism. Journal of Biomolecular Structure and Dynamics, 2019, 37, 2695-2702.	2.0	2
14	Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126577.	1.0	4
15	Preclinical Evaluation of Amphihevir, a First-in-Class Clinical Hepatitis C Virus NS4B Inhibitor. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	3
16	Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis. European Journal of Medicinal Chemistry, 2019, 179, 182-195.	2.6	11
17	A novel benzoxazinone derivative YLT-LL-11 inhibits diffuse large B-cell lymphoma growth via inducing cell cycle arrest and apoptosis. Bioscience Reports, 2019, 39, .	1.1	1
18	Structural and functional studies on Pseudomonas aeruginosa DspI: implications for its role in DSF biosynthesis. Scientific Reports, 2018, 8, 3928.	1.6	20

#	Article	IF	Citations
19	Metabolism of SKLB-TB1001, a Potent Antituberculosis Agent, in Animals. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	4
20	Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. Cell Death and Disease, 2018, 8, e2534-e2534.	2.7	72
21	YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Cell Death and Disease, 2018, 9, 1066.	2.7	38
22	A novel benzothiazinethione analogue SKLB-TB1001 displays potent antimycobacterial activities in a series of murine models. Biomedicine and Pharmacotherapy, 2017, 88, 603-609.	2.5	4
23	Synthesis and biological evaluation of (E)-4-(3-arylvinyl-1H-indazol-6-yl)pyrimidin-2-amine derivatives as PLK4 inhibitors for the treatment of breast cancer. RSC Advances, 2017, 7, 27737-27746.	1.7	21
24	Selective and efficient synthesis of trans-arylvinylboronates and trans-hetarylvinylboronates using palladium catalyzed cross-coupling. New Journal of Chemistry, 2017, 41, 3172-3176.	1.4	14
25	Mannosylated liposomes improve therapeutic effects of paclitaxel in colon cancer models. Journal of Microencapsulation, 2017, 34, 513-521.	1.2	34
26	Synthesis and biological evaluation of N-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)benzenesulfonamide derivatives as new BET bromodomain inhibitors for anti-hematologic malignancies activities. Molecular Diversity, 2017, 21, 125-136.	2.1	2
27	Structureâ€“Function Relationship of Aminopeptidase P from Pseudomonas aeruginosa. Frontiers in Microbiology, 2017, 8, 2385.	1.5	11
28	Small Molecule TH-39 Potentially Targets Hec1/Nek2 Interaction and Exhibits Antitumor Efficacy in K562 Cells via G0/G1 Cell Cycle Arrest and Apoptosis Induction. Cellular Physiology and Biochemistry, 2016, 40, 297-308.	1.1	11
29	A novel small-molecule YLT256 inhibits proliferation and induces apoptosis both in vitro and in vivo in solid tumors. Biomedicine and Pharmacotherapy, 2016, 81, 482-490.	2.5	1
30	ZLD1122, a novel EZH2 and EZH1 small molecular inhibitor, blocks H3K27 methylation and diffuse large B cell lymphoma cell growth. RSC Advances, 2016, 6, 28512-28521.	1.7	11
31	A new series of HCV inhibitors based on a 2-(thieno[2,3b]pyridin-2-yl)-1,3,4-oxadiazole scaffold. RSC Advances, 2016, 6, 40277-40286.	1.7	11
32	Nifuroxazide exerts potent anti-tumor and anti-metastasis activity in melanoma. Scientific Reports, 2016, 6, 20253.	1.6	61
33	Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer. Scientific Reports, 2016, 6, 20864.	1.6	46
34	Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis. Scientific Reports, 2016, 6, 29717.	1.6	31
35	Identification of novel 2-aminothiazole conjugated nitrofuran as antitubercular and antibacterial agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 3669-3674.	1.0	27
36	A novel benzothiazole derivative SKLB826 inhibits human hepatocellular carcinoma growth via inducing G2/M phase arrest and apoptosis. RSC Advances, 2015, 5, 41341-41351.	1.7	9

#	Article	IF	Citations
37	Discovery of Imidazo[2,1-b]thiazole HCV NS4B Inhibitors Exhibiting Synergistic Effect with Other Direct-Acting Antiviral Agents. Journal of Medicinal Chemistry, 2015, 58, 2764-2778.	2.9	40
38	Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-Nâ€²-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo. Bioorganic and Medicinal Chemistry, 2015, 23, 4333-4343.	1.4	14
39	Synthesis and biological evaluation of N-(4-phenylthiazol-2-yl)cinnamamide derivatives as novel potential anti-tumor agents. MedChemComm, 2015, 6, 1036-1042.	3.5	12
40	Design, synthesis and biological evaluation of novel 1-methyl-3-oxo-2,3,5,6,7,8-hexahydroisoquinolins as potential EZH2 inhibitors. RSC Advances, 2015, 5, 25967-25978.	1.7	15
41	Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1,3-benzothiazin-4-one derivatives. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1373-1376.	1.0	39
42	The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model. PLoS ONE, 2014, 9, e85887.	1.1	101
43	A Novel Cinnamide YLT26 Induces Breast Cancer Cells ApoptosisviaROS-Mitochondrial Apoptotic Pathwayin Vitroand Inhibits Lung Metastasisin Vivo. Cellular Physiology and Biochemistry, 2014, 34, 1863-1876.	1.1	32
44	Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Breast Cancer Research and Treatment, 2014, 143, 435-446.	1.1	57
45	Discovery and structureâ€“activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1581-1588.	1.0	43
46	SKLB316, a novel small-molecule inhibitor of cell-cycle progression, induces G2/M phase arrest and apoptosis in vitro and inhibits tumor growth in vivo. Cancer Letters, 2014, 355, 297-309.	3.2	34
47	A Novel Small-Molecule YLT205 Induces Apoptosis in Human Colorectal CellsviaMitochondrial Apoptosis PathwayIn Vitroand Inhibits Tumor GrowthIn Vivo. Cellular Physiology and Biochemistry, 2014, 33, 933-944.	1.1	22
48	Synthesis and structureâ€“activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4919-4922.	1.0	55
49	Pharmacokinetic Studies of a Novel Multikinase Inhibitor for Treating Cancer by HPLC-UV. Journal of Chromatographic Science, 2013, 51, 17-20.	0.7	5
50	The New Convenient Synthesis of 6-Fluoropurine and Its 7-/9-Unsubstituted Analogues. Heterocycles, 2012, 85, 2999.	0.4	3
51	6-Chloro-9-(2-nitrophenylsulfonyl)-9H-purine. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o687-o687.	0.2	0